CIBC World Cuts Syneron Medical to Sector Perform

Warns of the risk that product cycles slow down and says that the medical products maker isn't likely to meet expectations about its revenues

CIBC World downgraded Syneron Medical (ELOS ) to sector perform from outperform, explaining that the medical products maker isn't likely to hit the $29 million consensus revenue estimate in the fourth quarter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.